NCT07164313 2026-04-14A Study of ZW251 in Participants With Advanced Solid TumorsZymeworks BC Inc.Phase 1 Recruiting100 enrolled
NCT04198766 2025-12-18Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Inhibrx Biosciences, IncPhase 1/2 Active not recruiting296 enrolled
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT03685591 2024-06-26PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsPfizerPhase 1 Terminated49 enrolled 33 charts
NCT02164461 2024-05-20Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerAdvaxis, Inc.Phase 1 Completed12 enrolled 18 charts
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled